A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
DC Field | Value | Language |
---|---|---|
dc.contributor.author | You, Byung Chul | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Kim, Hun il | - |
dc.contributor.author | Kim, Se Hun | - |
dc.contributor.author | Park, Seung Sik | - |
dc.contributor.author | Seo, Yu Ri | - |
dc.contributor.author | Kim, Sang Gyune | - |
dc.contributor.author | Lee, Se Whan | - |
dc.contributor.author | Kim, Hong Soo | - |
dc.contributor.author | Jeong, Soung Won | - |
dc.contributor.author | Jang, Jae Young | - |
dc.contributor.author | Kim, Boo Sung | - |
dc.date.accessioned | 2021-08-12T02:46:40Z | - |
dc.date.available | 2021-08-12T02:46:40Z | - |
dc.date.issued | 2012-09 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.issn | 2287-285X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/14912 | - |
dc.description.abstract | Background/ Aims: When combined with pegylated interferon alpha-2b (Peg-IFN a-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients than for patients in Western countries, current guidelines might result in Korean patients being overdosed with RBV. Methods: We retrospectively reviewed the medical records of patients with genotype 1 CHC who were treated with PegIFN alpha-2b and RBV combination therapy. We divided the patients into groups A (>= 15 mg/kg/day, n >= 23) and B (< 15 mg/kg/day, n=26), given that the standard dose is 15 mg/kg/day. The clinical course in terms of the virologic response, adverse events, and dose modification rate was compared between the two groups after therapy completion. Results: The early response rates (92.0% vs. 83.3%, P=0.634) and sustained virologic response rates (82.6% vs. 73.1%, P=0.506) did not differ significantly between the two groups. During the treatment period, the RBV dose reduction rate was significantly higher in group A than in group B (60.9% vs. 23.1%, P=0.01). Conclusions: RBV dose reduction is performed frequently when patients are treated according to the current Korean guidelines. Given that lowering the RBV dose did not appear to decrease the virologic response during therapy, reducing RBV doses below the current Korean guideline may be effective for treatment, especially in low-weight patients. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한간학회 | - |
dc.title | A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3350/cmh.2012.18.3.272 | - |
dc.identifier.wosid | 000409412200004 | - |
dc.identifier.bibliographicCitation | Clinical and Molecular Hepatology, v.18, no.3, pp 272 - 278 | - |
dc.citation.title | Clinical and Molecular Hepatology | - |
dc.citation.volume | 18 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 272 | - |
dc.citation.endPage | 278 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001696172 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordAuthor | Ribavirin | - |
dc.subject.keywordAuthor | Pegylated interferon alpha-2b | - |
dc.subject.keywordAuthor | Chronic hepatitis C | - |
dc.subject.keywordAuthor | Sustained virologic response | - |
dc.subject.keywordAuthor | Koreans | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.